Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual
Expect to Complete 12-months treatment in June, 2024
Related news for (VCNX)
- Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
- Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
- Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
- Vaccinex Announces Receipt of Delisting Notification from Nasdaq
- Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update